Medibank Pvt (ASX:MPL) Research & Development: A$0 Mil (TTM As of Dec. 2025)


ASX:MPL Medibank Pvt Ltd ASX:MPL
77 GF Score
Price A$4.99
GF Value A$4.38
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medibank Pvt Research & Development?

Medibank Pvt ASX:MPL +2.67% 77 Research & Development is A$0 Mil as of Dec. 2025. GuruFocus rates ASX:MPL with a GF Score™ of 77/100 and a GF Value™ of A$4.38 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medibank Pvt's Research & Development for the six months ended in Dec. 2025 was A$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0 Mil.

Medibank Pvt  (ASX:MPL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medibank Pvt Research & Development Related Terms

Medibank Pvt Research & Development Historical Data

* Premium members only.

The historical data trend for Medibank Pvt's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medibank Pvt Research & Development Chart

Medibank Pvt Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medibank Pvt Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:MPL
77GF Score
Medibank Pvt Ltd ASX:MPL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medibank Pvt Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0 Mil mean?
Medibank Pvt (ASX:MPL) has a Research & Development of A$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medibank Pvt and its competitors.
Is Medibank Pvt's Research & Development too high?
Medibank Pvt's current Research & Development is A$0 Mil. Overall, Medibank Pvt has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medibank Pvt's Research & Development compare to FNF and AXS?
Medibank Pvt's Research & Development of A$0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medibank Pvt and its competitors. Medibank Pvt's current Research & Development is A$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medibank Pvt stock overvalued right now?
Based on GuruFocus' analysis, Medibank Pvt (ASX:MPL) is currently considered Modestly Overvalued. The stock's GF Value™ is A$4.38, compared to a current price of A$4.99 — trading 13.9% above its estimated fair value. The current Research & Development is A$0 Mil. Medibank Pvt's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medibank Pvt (ASX:MPL), the current Research & Development is A$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medibank Pvt (ASX:MPL) Overvalued in 2026?

Based on GuruFocus' analysis, Medibank Pvt stock appears to be overvalued. The current stock price of A$4.99 is trading 13.9% above its estimated GF Value™ of A$4.38. GuruFocus considers Medibank Pvt to be Modestly Overvalued.

Key valuation signals for ASX:MPL:

  • Research & Development: A$0 Mil
  • GF Value™: A$4.38 vs. price of A$4.99 (13.9% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the ASX:MPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medibank Pvt Business Description

Other Exchanges MDBPF:USAMDBKY:USA
Address 695 Collins Street, Medibank Melbourne Hub, Level 2, Docklands, Melbourne, VIC, AUS, 3008
Previously owned by the Australian government, Medibank is the largest health insurer in Australia. Its two brands, Medibank Private and Ahm, cover around 5 million people. Medibank and Australia's fourth-largest health fund, NIB Holdings, are the only listed health insurers. In addition to private health insurance, the firm provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.
77GF Score

Get the complete analysis for ASX:MPL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.99
Price
A$4.38
GF Value